Endogenous t-cell therapy: Clinical experience

Cancer Journal (United States)

Volumn 21, Issue 6, 2015, Pages 492-500

  Yee, Cassian ^a   Lizee, Greg ^a   Schueneman, Aaron J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adoptive T cell therapy; Antigen specific T cells; Combination immunotherapy; Endogenous T cell therapy; Melanoma; Memory T cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL STUDY; ENDOGENOUS T CELL THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; MELANOMA; PATHOLOGY; PROCEDURES;

LYMPHOCYTE ANTIGEN RECEPTOR;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; RECEPTORS, ANTIGEN, T-CELL;

EID: 84948396356     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000158     Document Type: Review

References (43)

1. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci. 1954; 143: 58-80.
2. Delorme EJ, Alexander P. Treatment of primary fibrosarcoma in the rat with immune lymphocytes. Lancet. 1964; 2: 117-120.
3. Fefer A. Immunotherapy and chemotherapy of Moloney sarcoma virusinduced tumors in mice. Cancer Res. 1969; 29: 2177-2183.
4. Fernandez-Cruz E, Woda BA, Feldman JD. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med. 1980; 152: 823-841.
5. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J ExpMed. 1980; 151: 69-80.
6. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976; 193: 1007-1008.
7. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988; 319: 1676-1680.
8. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med. 2015; 7: 280ps7.
9. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348: 62-68.
10. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994; 91: 2105-2109.
11. Tsai V, Southwood S, Sidney J, et al. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997; 158: 1796-1802.
12. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol. 1995; 154: 2257-2265.
13. +) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999; 190: 705-715.
14. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. NatMed. 1999; 5: 677-685.
15. Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999; 162: 2227-2234.
16. LiaoX, LiY, Bonini C, et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004; 9: 757-764.
17. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004; 199: 251-263.
18. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003; 5: 654-667.
19. + T cell clones fromthe peripheral blood ofmelanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 1996; 157: 4079-4086.
20. + T cells: implications for tumor immunotherapy. Immunity. 1996; 4: 555-564.
21. SuhoskiMM, Golovina TN, Aqui NA, et al. Engineering artificial antigenpresenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007; 15: 981-988.
22. + T cells. Sci Transl Med. 2011; 3: 80ra34.
23. DudleyME, Wunderlich J, NishimuraMI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001; 24: 363-373.
24. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002; 99: 16168-16173.
25. Meidenbauer N, Marienhagen J, LaumerM, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003; 170: 2161-2169.
26. + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006; 24: 5060-5069.
27. + T cells against NY-ESO-1. N Engl J Med. 2008; 358: 2698-2703.
28. Khammari A, Labarrière N, Vignard V, et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J InvestDermatol. 2009; 129: 2835-2842.
29. Wallen H, Thompson JA, Reilly JZ, et al. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009; 4: e4749.
30. + T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109: 4592-4597.
31. + T cells can mediate antileukemic activity and persist in posttransplant patients. Sci Transl Med. 2013; 5: 174ra27.
32. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 1988; 65: 87-92.
33. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-854.
34. Buckner CD, Clift RA, Fefer A, et al. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms. Cancer Chemother Rep. 1974; 58: 709-714.
35. + T cells derived fromcentral memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008; 118: 294-305.
36. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005; 175: 2261-2269.
37. +) T cells. J Immunother Cancer. 2014; 2: 36.
38. Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013; 121: 573-584.
39. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011; 17: 1290-1297.
40. van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of secondgeneration chimeric antigen receptors. Nat Rev Drug Discov. 2015; 14: 499-509.
41. Aranda F, Vacchelli E, Eggermont A, et al. Trial Watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014; 3: e27297.
42. Lizée G, Overwijk WW, Radvanyi L, et al. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64: 71-90.
43. Altman JD, Moss PAH, Goulder PJR, Barouch DH, et al. Phenotypic analysis of antigen-specific T lymphocytes. [published erratum appears in Science 1998; 280: 1821]. Science. 274: 94-96.